|
|
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate
|
|
|
|
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
|
|
|
|
Emergent BioSolutions Announces Addition to Russell 3000® Index
|
|
|
|
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
|
|
|
|
NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF DERIVATIVE ACTIONS
|
|
|
|
Summary Notice of Pendency and Proposed Settlement of Derivative Actions
|
|
|
|
Emergent BioSolutions to Participate in Upcoming Investor Conferences
|
|
|
|
Emergent BioSolutions Reports First Quarter 2025 Financial Results
|
|
|
|
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
|
|
|
|
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
|
|
|
|
Emergent BioSolutions Announces Stock Repurchase Program
|
|
|
|
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
|
|
|
|
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
|
|
|
|
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
|
|
|
|
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
|
|
|
|
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
|
|
|
|
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
|
|
|
|
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
|
|
|
|
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
|
|
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
|
|
|
|
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
|
|
|
|
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
|
|
|
|
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
|
|
|
|
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
|
|
|
|
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
|
|
|
|
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
|
|
